Key result
Cystatin C and B2M improve mortality risk reclassification ~32% over eGFR in carotid atherosclerosis.
Why the study?
It remains unclear which renal function parameter among eGFR, cystatin C, and beta-2-microglobulin is the strongest predictor of mortality in patients with atherosclerosis.
Are cystatin C and beta-2-microglobulin stronger predictors of long-term mortality than eGFR in patients with asymptomatic carotid atherosclerosis?
Cohort (n=1,065)
Are cystatin C and beta-2-microglobulin stronger predictors of long-term mortality than eGFR in patients with asymptomatic carotid atherosclerosis?
Effect estimate: NRI 32.4% for CysC and 29% for B2M
p-value: p=<0.0001
Cystatin C and beta-2-microglobulin are superior to eGFR for predicting long-term mortality in patients with asymptomatic carotid atherosclerosis.
May enhance mortality risk stratification beyond eGFR in carotid atherosclerosis; leaves open whether adoption improves outcomes or guides therapy.
Renal dysfunction is a risk factor for mortality in patients with atherosclerosis. Estimated glomerular filtration rate (eGFR), cystatin C (CysC) and beta-2-microglobulin (B2M) are measures of renal function. It remains unclear, which of these parameters is the strongest predictor of outcome in patients with atherosclerosis. All-cause and cardiovascular mortality were prospectively investigated in 1,065 consecutive patients with asymptomatic carotid atherosclerosis. During a median follow-up of 6.3 years 275 patients died (25.8%), including 182 (66.2%) from cardiovascular causes. Estimated GFR, CysC and B2M were all significantly and independently associated with mortality. Inclusion of the renal parameters CysC and B2M but not of eGFR into a model with established cardiovascular risk factors improved the C-statistics significantly (p=0.0035 and 0.036, respectively; p=0.182 for eGFR). The net reclassification improvement (NRI) was 32.4% (p<0.0001) for CysC, 29% (p<0.0001) for B2M, and 16.5% (p=0.019) for eGFR. The integrated discrimination improvement (IDI) was 0.014 (p=0.0009) for CysC and 0.011 (p=0.005) for B2M while it was not significant for eGFR. Results were consistent for various subgroups with different extent of atherosclerosis. In summary, CysC and B2M were found to be independent predictors for mortality and had superior predictive value compared to eGFR in patients with asymptomatic carotid atherosclerosis. The clinical importance of these findings has to be validated in larger studies with a community-based approach.
No takes yet. Share an insight, caveat, or question.
Pernicka et al. (2011) conducted a cohort in asymptomatic carotid atherosclerosis (n=1,065). Cystatin C and beta-2-microglobulin vs. Estimated glomerular filtration rate (eGFR) was evaluated on All-cause and cardiovascular mortality (NRI 32.4% for CysC and 29% for B2M, p=<0.0001). Cystatin C and beta-2-microglobulin significantly improved mortality risk reclassification (NRI 32.4% and 29%, respectively; both P<0.0001) compared to eGFR in asymptomatic carotid atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: